April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
A Swiss Patient Cohort Reveals Genetic Predisposition Of Known And New Genetic Loci To AMD And To Intravitreal Ranibizumab (lucentis®) Treatment Outcome
Barbara Kloeckener-Gruissem; Moreno Menghini; Daniel Barthelmes; Stephan Labs; Malaika Kurz-Levin; Stephan Michels; Johannes Fleischhauer; Florian Sutter; Wolfgang Berger
Author Affiliations & Notes
  • Barbara Kloeckener-Gruissem
    Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland
    Department of Biology, ETH, Zurich, Switzerland
  • Moreno Menghini
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • Daniel Barthelmes
    Save Sight Institute, University of Sydney, Sydney, Australia
  • Stephan Labs
    Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland
  • Malaika Kurz-Levin
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • Stephan Michels
    Augenklinik, Stadtspital Triemli, Zurich, Switzerland
  • Johannes Fleischhauer
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • Florian Sutter
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • Wolfgang Berger
    Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland
  • Footnotes
    Commercial Relationships  Barbara Kloeckener-Gruissem, None; Moreno Menghini, None; Daniel Barthelmes, None; Stephan Labs, None; Malaika Kurz-Levin, None; Stephan Michels, None; Johannes Fleischhauer, None; Florian Sutter, None; Wolfgang Berger, None
  • Footnotes
    Support  unrestricted research grant of Novartis Pharma Schweiz AG
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5249. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      A Swiss Patient Cohort Reveals Genetic Predisposition Of Known And New Genetic Loci To AMD And To Intravitreal Ranibizumab (lucentis®) Treatment Outcome
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Barbara Kloeckener-Gruissem, Moreno Menghini, Daniel Barthelmes, Stephan Labs, Malaika Kurz-Levin, Stephan Michels, Johannes Fleischhauer, Florian Sutter, Wolfgang Berger; A Swiss Patient Cohort Reveals Genetic Predisposition Of Known And New Genetic Loci To AMD And To Intravitreal Ranibizumab (lucentis®) Treatment Outcome. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5249.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Current standard treatment for neovascular age-related macular degeneration (AMD) is intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Within a Swiss patient population we searched for genetic factors that influence AMD and that affect the outcome of ranibizumab treatment.

Methods: : Changes of visual acuity (VA) were measured during 12 months after initiation of anti-VEGF treatment and percentiles of VA course were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2 and VEGFA) as well as not yet reported AMD associated candidate genes (KDR, LRP5 and FZD4) were determined and their frequencies compared.

Results: : We completed VA assessment for 243 eyes. On average, approximately four ranibizumab injections were administered. Based on the change of visual acuity, two responder groups were established: poor responders (25th percentile) and good responders (75th percentile) each containing 63 eyes. Individuals with genotypes CT and TT of p.Y402H in CFH were about 3.5 times more likely to improve visual acuity (p=0.006), while individuals with genotype CC did not fair well. Furthermore, individuals simultaneously heterozygous at SNPs in the two loci, CFH (p.Y402H) and FZD4 (SNP rs10898563) showed improved visual acuity (p=0.0044) compared to the not heterozygous patients. Association with AMD was confirmed at the known genetic susceptibility loci CFH, HTRA1 and AMRS2 and furthermore we identified a risk conferring polymorphism in one new locus, LRP5.

Conclusions: : Genetic predisposition is likely to account for the variability in response to anti-VEGF treatment. LRP5 and FZD4, two proteins involved in retinal vascular development as co-receptors of the Wnt-signalling pathway, may also influence the development of AMD and response to treatment with anti VEGF, respectively.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: risk factor assessment • candidate gene analysis 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept